



BIOMM S.A.

Public Held Company

CNPJ/ME nº 04.752.991/0001-10

NIRE nº 31.300.016.510

MATERIAL FACT

BIOMM S.A. ("Company" or "Biommm"), in compliance with the provisions of Resolution of the Brazilian Securities Commission No. 44 of August 23, 2021, hereby informs its shareholders and the market in general that, on the date hereof, it was published in the Official Gazette (DOU) the Certificate of Good Manufacturing Practices (GMP) with approval of the stages of manufacturing sterile products at Biommm's biopharmaceutical plant in Nova Lima, Minas Gerais.

It is worth mentioning that the biopharmaceutical plant was already certified with the GMP to execute the secondary packaging of sterile medicines since September 2019. Subsequently, the Company requested from the Brazilian Health Regulatory Agency (ANVISA) the GMP to include the stages of manufacturing sterile products (formulation and filling) and it was granted on today's date with the publication in the Official Gazette (Resolution-RE No. nº 2.149 de 15/06/2023).

More recently, the Company completed the production of Glargilin® (insulin glargine) batches at its biopharmaceutical plant and they are undergoing a stability study.

Biommm will keep its shareholders and the market in general informed of the development of the subject matter of this material fact.

Nova Lima/MG, June 19th, 2023

Mirna Santiago Vieira

Chief Financial and Investor Relations Officer